Timing and indications of surgery in stenotic and regurgitant valvular lesions Dr.Deepak Raju.

Slides:



Advertisements
Similar presentations
Underwriting Impact of New Advances in Valvular Heart Disease NEHOUA 2012 Michael Clark, FACC, FLMI, FBIM Chief Medical Director Swiss Re.
Advertisements

Left Ventricular Pressure-Volume Loops
Aortic Stenosis Obstruction to outflow is most commonly localized to the aortic valve. However, obstruction may also occur above or below the valve.
New Developments in the Management of Aortic and Mitral Valve Disorders New Developments in the Management of Aortic and Mitral Valve Disorders Patricia.
© Continuing Medical Implementation …...bridging the care gap Valvular Heart Disease Aortic Regurgitation.
Evaluation and Management of Asymptomatic Aortic Stenosis. Augusto Pichard, M.D. Director Innovation and Structural Heart Disease, Vice Chair, Medstar.
Trileaflet Aortic Valve. Management strategy for patients with chronic severe aortic regurgitation. Preoperative coronary angiography should be performed.
© Continuing Medical Implementation …...bridging the care gap Valvular Heart Disease Aortic Stenosis.
Current Treatment and Future Trends Anthony J. Palazzo, M.D.F.A.C.S.
Cardioanaesthesia. Coronary artery disease O 2 delivery Coronary blood flow = directly related to coronary perfusion pressure (CPP) CPP = aortic diastolic.
Aortic Regurgitation Mohammed AL Ghamdi.
Some Essentials of Valvular Heart Disease CCU lecture series.
Asymptomatic Aortic Stenosis and Exercise Test
1 Cardiac Pathophysiology Part B. 2 Heart Failure The heart as a pump is insufficient to meet the metabolic requirements of tissues. Can be due to: –
Bio-Med 350 Normal Heart Function and Congestive Heart Failure.
Valvular heart disease Mitral Valve Diseases
Valvular Heart Disease. Normal heart valves function to maintain the direction of blood flow through the atria and ventricles to the rest of the body.
VALVULAR HEART DISEASE. BY DR GHULAM HUSSAIN. MBBS, Diploma in Cardiology, MD (Medicine) Assistant Professor of Medicine Medical Unit-4 LUMHS, Jamshoro.
Guidelines for the Management of Patients With Aortic Valve Disease Dr sajeer K T Senior Resident, Dept. of Cardiology, MCH, Calicut.
HEART FAILURE PROF. DR. MUHAMMAD AKBAR CHAUDHRY M.R.C.P.(U.K) F.R.C.P.(E) F.R.C.P.(LONDON) F.A.C.C. DESIGNED AT A.V. DEPTT F.J.M.C. BY RABIA KAZMI.
Diastolic Dysfunction as Diagnosed and Quantified by Echocardiography LAM-1965AO (07/13) For Broker/Dealer Use Only.
Ventricular Diastolic Filling and Function
Aetiology * MVP { Myxomatous mv },commonest in developed world *Damage to the cusps : _RVD _ IE _ Congenital Cleft MV *Damage to chordae : _RVD.
Common Clinical Scenarios *Younger people *Younger people _Functional murmur vs _Functional murmur vs _ MVP vs _ MVP vs _ AS _ AS *Older people _Aortic.
RJS Valvular heart disease Richard Schilling St Mary’s Hospital London.
Valvular Heart DISEASE
Inflammatory and Structural Heart Disorders Valvular Heart Disease
Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation Right Ventricular Function and Pulmonary Artery Hypertension After Degenerative.
1 بسم الله الرحمن الرحیم. Atrial and Ventricular Hypertrophy ECG Features and Common Causes ALI BARABADI University of Guilan.
AORTIC REGURGITATION AORTIC REGURGITATION ETIOLOGY LEAFLETS: RHEUMATIC H.D. CALCIFIED PROLAPSE ENDOCARDITIS TRAUMA RHEUMATOID ARTHRITIS ANNULUS, ROOT.
Valve Surgery V.Rohn. Valve Surgery History before the era of ECC 1925 – Suttar – first successful digital commisurolysis of mitral valve 1952 – Hufnagel.
Aortic Insufficiency Acute and Chronic
Mitral Regurgitation. Abnormalities of the Mitral Valve Valve Leaflets Chordae Tendineae Papillary Muscles Mitral Annulus.
Guidelines for the Echocardiographic Assessment of
Adult Cardiac Valve Disease Marvin D. Peyton, M.D. Thoracic and Cardiovascular Surgery University of Oklahoma Health Sciences Center.
Ryan Hampton OMS IV January  Considerations Is MR severe? Is patient symptomatic? Is patient a good candidate? What is Left Ventricular function?
Valvular Heart Disease
Pathophysiology BMS 243 Rheumatic Heart Disease
ADULT ECHOCARDIOGRAPHY Lesson Nine Valvular Heart Disease
Exercise Management Chronic Heart Failure Chapter 12.
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2014 AHA/ACC Guideline for the Management of Patients.
Asymptomatic mitral regurgitation When should you operate? Ben Bridgewater Cardiac surgeon and lead clinician, UHSM, Manchester Honorary Reader, Manchester.
Causes of Heart Valve Dysfunction Congenital defects (bicuspid aortic valve) Infections (rheumatic fever and bacterial endocarditis Coronary artery disease.
Echo conference R4 우종신 R4 우종신. Case 1 한 O 태 () Evaluation of severity Planimetry of mitral orifice Planimetry of mitral orifice –only direct measurement.
Date of download: 6/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Emerging Role of Exercise Testing and Stress.
EXPANDING INDICATIONS OF TRANSCATHETER HEART VALVE INTERVENTIONS. JACC CARDIOVASCULAR INTERVENTION. DR.RAJAT GANDHI.
Thanks ………… Echocardiographic Evaluation Of Prosthetic Cardiac Valves Dr Gaurav Kumar Chaudhary MD,DM( Cardiology) Assistant Professor Department of Cardiology.
Date of download: 7/7/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA guidelines for the management of patients.
Primary Mitral Regurgitation Degenerative Mitral Valve Disease
Cath. Data. Dilated Cardiomyopathy.
© free-ppt-templates.com 2017 AHA/ACC Focused Update of Valvular Heart Disease Guideline of 2014 DR. OMAR SHAHID TR CARDIOLOGY SZH.
MITRAL STENOSIS Dr R Schulenburg Division of Adult Cardiac Surgery,
Heart & Thalassemia . R.Miri,MD, Interventional Cardiologist.
Mitral Regurgitation: Epidemiology, Pathophysiology and When to Repair
Cardiothoracic Surgery
University of Pennsylvania Philadelphia
AORTIC STENOSIS.
ADULT ECHOCARDIOGRAPHY Lecture Five The Aortic Valve
DIASTOLIC DYSFUNCTION and DIASTOLIC HEART FAILURE
Pathophysiology BMS 243 Rheumatic Heart Disease
Dr M B Connellan Stellenbosch University
Normal physiology (control) is compared to that of acute mitral regurgitation (chordal rupture), compensated mitral regurgitation, and decompensated chronic.
ADULT ECHOCARDIOGRAPHY Lecture Five The Aortic Valve
Circ Cardiovasc Imaging
Aortic regurgitation.
Zoll Firm Lecture Series
Ανεπάρκεια Μιτροειδούς : Σταυρόλεξο για δυνατούς λύτες Ποσοτικοποίηση με Ηχωκαρδιογράφημα και ο ρόλος των δοκιμασιών φόρτισης Μαρία Μπόνου Διευθύντρια,
AORTIC VALVE Aortic Valve is located at the junction of LV outflow tract and ascending Aorta. Aortic valve consists of 3 components – annulus, cusp and.
Slides courtesy of Dr. Randall Harada
Patrick O’Gara et al. JIMG 2008;1:
Presentation transcript:

Timing and indications of surgery in stenotic and regurgitant valvular lesions Dr.Deepak Raju

Aortic stenosis Pathophysiology Assessment of severity Natural history Management strategy Role of exercise test,EBCT Recommendations

Concept of afterload mismatch Term coined by Ross et al (1976) Increasing aortic pressure increased LV contractility,LV volume and mass kept constant At a particular level contractility started decreasing-mismatch b/w afterload and contractile state

AS-pathophysiology Increasing severity of AS-matched by increasing LV mass and contractility Compensation by hypertrophy fails to sustain afterload Clinical afterload mismatch occurs LV utilizes preload reserve-mechanism by which stroke volume is maintained by increasing preload Preload reserve is not a good compensatory mechanism in AS(LV on steep portion of diastolic pressure volume loop) Systolic pump function fails once preload reserve is no longer adequate Earliest stage of LV dysfunction in severe AS

LV systolic dysfunction – Afterload mismatch and/or impaired contractility LV diastolic dysfunction – Laplace equation Stress =pressure.radius/2.wall thickness – Increased wall thickness compensates for pressure overload – Impaired relaxation&altered compliance-Diastolic dysfunction – Atrial booster pump maintains LV filling

Assessment of severity Jet velocity-reproducible,strongest predictor of clinical outcome Aortic valve area-continuity equation Velocity ratio- – suboptimal image of LVOT – effectively indexed for BSA – Ratio <0.25 indicates severe stenosis

Other measures of severity Stroke work loss – Ratio of mean PG to mean LV pressure – >26% predictive of probability of cardiac death or AVR Energy loss index – Calculated from aortic valve area and area of aorta at sinotubular junction – Severe AS <0.55 cm2/m2 Valvulo arterial impedance – Reflects degree of valve obstruction,ventricular response and systemic vascular impedance – survival lower in patients with Zva >4.5 mmHg/ml/m2 (Zeineb et al JACC 2009)

Natural history Prolonged latent period Rate of progression of stenosis of moderate severity – Jet velocity 0.3 m/s/yr – Gradient 7 mmHg/yr – Area 0.1 cm2/yr

Asymptomatic adult-AS

Pellikka et al.circulation 2005,622 pts,mean follow up 5.4 yr

Other findings(Pellikka et al ) – Patients with jet velocity >4.5 m/s had greater likelihood of develpoing symptoms(relative risk 1.34) – Incidence of sudden cardiac death was 1% /yr

Asymptomatic patient-AS Patients with asymptomatic severe AS require frequent monitoring for devt.of symptoms In a meta analysis of seven studies the risk of sudden cardiac death was found to be 0.4%/yr(375 pts,mean follow up 2.1 yr)

Follow up – Clinical frequent monitoring for devt of symptoms every year for mild 6 mth for moderate and severe – TTE Every year for severe AS 1-2 year for moderate AS 3-5 year for mild AS – Patient education regarding devt of symptoms

Exercise testing May be considered in asymptomatic patients with unclear symptoms to elicit(IIb) – limited exercise capacity – exercise induced symptoms – Abnormal BP response

Amato et al 2001,Heart 2001 – 66pts,14 mth follow up – Positive stress rest Horizontal or downsloping ST dep>1 mm (men ) &2mm (women)or upsloping ST>3mm in men Angina,near syncope Ventricular arrhythmia SBP fails to rise by 20 mmHg – Grp with Abnormal exercise response 19% symptom free survival at 2 yrs – Normal 85% symptom free survival at 2 yrs – 6% experienced SCD;all had positive stress test

Das P et al, Eur Heart J,2005 – 125 pts,12 mth follow up – Positive test Limiting symptoms(chest tightness,breathlessness,dizziness) Abnormal BP response(BP at peak exercise same or below baseline) ST dep >2mm – Exercise limiting symptoms independent predictor of outcome – Exercise brought out symptoms in 37% pts – In this group spontaneous symptoms developed in 51% compared to 11% in others

Management strategy In most asymptomatic patients with aortic stenosis,risk of surgery(3-4% for AVR-STS database) is higher than risk of watchful waiting Early surgery – older pts to higher mortality(8.8% in >65 yr, US medicare data) – Younger pts-morbidity and mortality of prosthetic valve

Early AVR may be considered – Severe valve calcification – Rapid progression Increase in jet velocity >0.3 m/s/yr Decrease in valve area >0.1 cm2 /yr – Expected delays in surgery

Symptomatic AS Critical point in natural history of AS Average survival is 2-3 years High risk of sudden cardiac death AVR improves symptoms and survival

Ross J Jr, Braunwald E: Aortic stenosis. Circulation 38:61, 1968

Low flow low gradient aortic stenosis Dobutamine stress echocardiography(IIa) – Transvalvular PG,valve area calculated in baseline and low dose dobutamine stress Severe AS-fixed valve area,increase in stroke volume and gradient AS not severe-valve area increases >0.2 cm2,increase stroke volume,no change in gradient Lack of contractile reserve-increase in stroke volume <20%-poor prognosis with medical or surgical therapy

Cardiac biomarkers Berger klein et al(circulation 2004) – 130 pts with severe AS – NT-BNP < 80 pmol/L predicted symptom free survival in asymptomatic patients followed up for one year(69% vs 18%)

EBCT Messika et al (circulation 2004) Valve calcification assessed by EBCT Event-free survival at 5 years was 92% Vs 40% comparing grps above and below 500 Agatston units

Recommendations for AVR Class I – Severe AS and symptoms – Severe AS (with or without symptom) need for CABG,valve replacement or aortic surgery – Severe AS and LV systolic dysfunction(EF <50 %) Class IIa – Moderate AS and need for other cardiac surgery

Class II b – asymptomatic severe AS With abnormal exercise response(devt.of symptoms,hypotension) Likelihood of rapid progression,expected delays at symptom onset Extremely severe AS(area 60mmHg,jet velocity>5 m/s) with expected mortality<1% Mild AS undergoing CABG,evidence of rapid progression Not useful for prevention of SCD in asymptomatic severe AS without above criteria

Aortic balloon valvotomy Class II b – Bridge to surgery in hemodynamically unstable patient who are at high risk for AVR – Palliation in whom AVR cannot be performed

Indications of BAV in adolescents and young adults Class I – Symptomatic AS(angina,syncope,DOE),PSG>50 mmHg,valve not heavily calcified – Asymptomatic,PSG >60 mmHg – Asymptomatic,PSG >50mmHg,with ST or T wave changes in left precordial leads at rest or with exercise Class II a – Asymptomatic,PSG > 50mmHg,wants to play competitive sports or planning pregnancy – When possible BAV preferred over surgery in adolescent or young adult

AR-Pathophysiology AR –volume overload and pressure overload Volume overload – ↑ EDV – ↑ chamber compliance – Combination concentric and eccentric hypertrophy Pressure overload – ↑ chamber size- ↑ wall stress-elevates afterload Preload reserve and compensatory hypertrophy maintain ejection performance-asymptomatic patient

Latent phase of AR, like AS, may last decades Decompensation – Preload reserve exhausted – Hypertrophy inadequate – Impaired contractility LV systolic dysfunction-initially reversible-afterload excess Impaired contractility predominates later-irreversible – Chamber enlargement – Spherical geometry LV systolic function and ESD-most important predictors of postoperative survival and recovery of LV function

Natural history Asymptomatic patient with normal LV function – 9 published studies,593 patients,mean follow up of 6.6 yrs – 25% of patients who die or develop LV dysfunction do so before the onset of symptoms – Quantitative evaluation of LV function indispensable

Natural history

End systolic dimension in relation to devt of symptoms,LV Dysfunction or death Bonow et al,circulation 1991 – ESD>50mm-19% /yr – ESD mm-6% /yr – ESD <40- 0%

Survival without surgery in symptomatic patients withAR

Symptomatic patients Poor outcome with medical therapy Mortality 10% /yr in patients with angina Mortality 20% /yr in heart failure

Indications for AVR or aortic valve repair Class I – Symptomatic severe AR – Asymptomatic severe AR with LVD(EF<0.50 at rest) CABG,valve surgery,aortic surgery Class II a – Asymptomatic severe AR with severe LV dilatation(EDD>75mm,ESD>55mm)

Class II b – Asymptomatic severe AR with borderline LV dilatation(EDD 70-75,ESD 50-55) abnormal hemodynamic response to exercise progressive LV dilatation Declining exercise tolerance – Moderate AR undergoing CABG or aortic surgery

Bicuspid aortic valve with dilated ascending aorta Class I – Surgery to repair aortic root or replacement of ascending aorta Diameter of ascending aorta or root >5cm Rate of increase in size >0.5 cm/yr Diameter>4.5 cm undergoing AVR

Mitral stenosis Narrowing of valve area to < 2.5 cm2 occurs before devt.of symptoms Symptoms at rest occur when valve area <1.5 cm2 Developed countries- – Long latent period from RF to symptoms (20-40 years) – A decade from symptom onset to disabling symptoms Rpted streptococcal infection and recurrent carditis-rapid progression in poor countries

Asymptomatic-10 yr survival-80% Symptomatic-0-15 % 10 yr survival Devt of PAH-mean survival <3 years annual loss of mtral valve area-0.09 cm2

Grading of severity MV area(cm2)Mean gradient(mmHg) PASP(mmHg) mild>1.5<5<30 Moderate severe<1.0>10>50

Indications for PMBV CLASS I – Symptomatic(II,III,IV) moderate or severe MS when valve morphology favourable – Asymptomatic moderate or severe MS,PASP>50 mmHg at rest or >60 mmHg with exercise Class IIa – Symptomatic (III,IV) moderate or severe MS,non pliable calcified valve if not candidates for surgery Class II b – Asymptomatic moderate MS when new AF – Symptomatic mild MS,exercise PASP >60 mmHg,PAWP>25mmHg,Mean grad >15 mmHg

Indications for surgery CLASS I – Symptomatic(III or IV),moderate or severe MS PMBV unavailable or contraindicated Valve morphology not favourable Moderate MR CLASS II a – MV replacement in severe MS,class I or II symptoms,PASP>60 mmHg and not considered for PMBV

Event free survival after BMV-50-65% at 3-7 yrs Survival higher (80%) in pts with favourable MV morphology

MS in young adults,adolescents Class I – Symptomatic(III,IV) with MV mean gradient >10 mmHg Class IIa – MV gradient >10mmHg with Mild symptoms Asymptomatic with PASP>50 mmHg Type of surgery – Parachute MV-creation of fenestration among fused chordae – Annulus enlarging operation-hypoplastic mitral annulus – Ballon dilatation in congenital MS-usefulness limited

MR -pathophysiology Increased preload,reduced or normal afterload Eccentric cardiac hypertrophy Increased LVEDV-compensated phase Prolonged hemodynamic overload ultimately leads to myocardial decompensation Ejection phase indices are initially higher in c/c MR due to reduced afterload Once decompensation occurs –start decreasing Values in low normal range reflect impaired myocardial function

Mitral regurgitation Mild to moderate MR –asymptomatic for years Severe MR-asymtomatic for years-compensated phase Natural history of severe MR due to flail leaflet- Sarano et al,1996 – At 10 years 90% required MVR or dead – Mortality -6-7% /yr in MR by flail leaflets in pts with symptoms(class III,IV) or LV dysfunction(EF<60%)

Asymptomatic patient with normal LV fn – Sarano et al 2005 EROA>40 mm2 had 4% /yr risk of cardiac death(198 pts follow up 2.7 yr) – Rosenhek et al, pts,5 yr follow up Indications of surgery were symptoms,LVD,LV dilatation,devt of PAH or AF One cardiac death in a patient who refused surgery

Surgery for asymptomatic patient with normal LV function –only considered if >90% likelihood of successful MV repair Rate of reoperation similar in MVR or MV repair(7% to 10%) at 10 yrs Operative mortality 2% for MV repair,6% for MVR(STS database)

Indications for surgery Class I – Symptomatic a/c severe MR – Symptomatic c/c severe MR(class II to IV) in the absence of severe LVD(EF 55mm) – Asymptomatic c/c severe MR with mild to moderate LVD(EF 30% to 60% and/or ESD >40mm) – MV repair recommended over MVR

Class II a – Asymptomatic severe MR with normal LV fn(EF >60% AND ESD<40 mm) if MV repair likely to be successful New onset AF,PAH(PASP >50 mmHg at rest or >60 mmHg with exercise) – Symptomatic severe MR with severe LVD,if MV repair likely Class II b – c/c severe MR secondary to severe LVD,persistent symptoms despite optimal therapy for heart failure

Tricuspid valve disease Severe TR –poor long term outcome due to RV dysfunction&systemic venous congestion Management strategy depends on clinical status and cause of tricuspid valve abnormality TR a/w dilatation of tricuspid annulus should be repaired – Tricuspid dilatation is an ongoing process – Annuloplasty improves functional status independent of degree of TR

Tricuspid valve and chordal reconstruction can be attempted in some cases(endocarditis,trauma) TVR- when leaflets themselves are diseased,abnormal or destroyed-bioprosthesis preferred TR should be addressed along with left sided valve surgery when annulus is dilated >70 mm peroperatively or >3.5 cm in TTE(Bianchi et al,2009)

Indications for tricuspid valve surgery Class I – Tricuspid valve repair for severe TR in patients with mitral valve d/s requiring mitral valve surgery Class II a – TVR or annuloplasty for severe primary TR when symptomatic – TVR for severe TR when not amenable to repair or annuloplasty Class II b – Tricuspid annuloplasty for less than severe TR in patients undergoing mitral valve surgery when there is pulmonary hypertension or annular dilatation

Pulmonary stenosis NHCHD study 564 pts – Medical management-46%(mild or moderate) Pressure gradients stable in majority 14% had significant increase of gradient – <2 years – PSG>40 mmHg 4% chance of increase gradients in other pts – surgery moderate to severe disease gradient decreased to insignificant levels in 90% No recurrence in follow up 14 yrs – 22 yr follow up of same cohort(1993) Pts with initial gradient <25 had 96% event free survival

Recommendations Class I – BPV recommended for symptomatic pt(exertional dyspnoea,angina,syncope,presyncope)with PSG>30 mmHg – Asymptomatic patient with PSG>40 mmHg Class II b – Asymptomatic patient with PSG>30-39 mmHg

Long term follow up of BPV similar to surgery with no recurrence –(10 yr follow up,Mc Crindle et al,circulation 1994 ) Surgery still required for dysplastic pulmonary valve

Pulmonary regurgitation Consequence of BPV or surgical valvotomy or TOF repair RV systolic dysfunction-9% Pulmonary valve replacement indicated in symptomatic patients(class III or IV) with severe PR Asymptomatic patients-before RV function deteriorates

THANK YOU